All stock lists
Kymera Therapeutics, Inc. (NASDAQ:KYMR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
114.35+3.59 (+3.24%)
Insider Score
––Not scored
KYMR Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
KYMR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 65.00 M | 34.37 M | 2.86 M | 2.76 M | 11.48 M | 22.10 M |
| Revenue Growth (YoY) | 466.40 % | 55.50 % | -61.32 % | -26.12 % | -55.26 % | 114.83 % |
| Cost of Revenue | 0.00 | 0.00 | -76.18 M | 74.09 M | 2.08 M | 0.00 |
| Gross Profit | 65.00 M | 34.37 M | 79.04 M | -71.33 M | 9.39 M | 22.10 M |
| SG&A Expense | 21.13 M | 20.36 M | 16.95 M | 17.34 M | 17.64 M | 16.27 M |
| R&D Expense | 119.48 M | 98.16 M | 83.86 M | 74.09 M | 78.39 M | 80.25 M |
| Operating Expenses | 140.61 M | 118.52 M | 176.93 M | 21.19 M | 93.95 M | 96.53 M |
| Operating Income | -75.61 M | -84.15 M | -97.90 M | -92.52 M | -84.56 M | -74.43 M |
| Pretax Income | -61.21 M | -69.23 M | -87.25 M | -82.17 M | -76.61 M | -65.58 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -61.21 M | -69.23 M | -87.03 M | -82.17 M | -76.61 M | -65.58 M |
| EPS (Basic) | -0.62 | -0.71 | -0.98 | -0.94 | -0.95 | -0.82 |
| EPS (Diluted) | -0.62 | -0.71 | -0.98 | -0.94 | -0.95 | -0.82 |
| Shares Outstanding | 98.18 M | 97.53 M | 84.39 M | 87.30 M | 80.45 M | 80.15 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.